The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. After an initial round of challenges launched in November ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended to delay generic competition. "By filing bogus patent listings, pharma ...
The Orange Book is a critical tool for drugmakers because they can sue a generic developer who applies for approval of a product with a listed patent, blocking the entry of a copycat medicine for 30 ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the agency said inhibits the generic drug market. The Federal Trade Commission ...
The FTC recently announced that it has sent another round of letters disputing additional patent listings in the FDA’s Orange Book. With this latest action, the FTC has now challenged hundreds ...
Agency challenges 300-plus patent listings in FDA registry November’s round of warnings has yielded mixed results Blockbusters including Novo Nordisk’s Ozempic and Victoza are among 20 branded drugs ...
《Federal Trade Commission》米国の連邦取引委員会。1914年設立の独立行政委員会。独占禁止法の実施状況の監査、反トラスト法に関する調査などを行う。